Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Arthritis, Rheumatoid 1

Interventions

Rituximab 67Cyclophosphamide 39Vincristine 33Prednisone 31Doxorubicin 25Lenalidomide 18Radiotherapy 16Bendamustine Hydrochloride 14Peripheral Blood Stem Cell Transplantation 10Filgrastim 10Etoposide 10Prednisolone 8tofacitinib 7obinutuzumab 6ibritumomab tiuxetan 6fludarabine 6VAP-cyclo protocol 6Mitoxantrone 6Methylprednisolone 6Deoxycholic Acid 6Cytarabine 6Melphalan 5Dexamethasone 5Carmustine 5ibrutinib 4fludarabine phosphate 4R-CHOP protocol 4Methotrexate 4Interferon-alpha 4Idarubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Follicular × RC-18 × Clear all
NCT03016013 2024-09-26

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

RemeGen Co., Ltd.

Phase 3 Completed
479 enrolled
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡